{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T06:14:48Z","timestamp":1771481688358,"version":"3.50.1"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Moyamoya disease is a rare, chronic cerebrovascular disorder characterized by progressive stenosis or occlusion of the terminal portions of the internal carotid arteries and the subsequent development of abnormal compensatory vascular networks. It represents a significant cause of intracranial arteriopathy and is a major etiology of stroke and transient ischemic attack in pediatric populations. We present the case of a 9-year-old boy with confirmed diagnosis of B-cell acute lymphoblastic leukemia (B-ALL), in whom brain MRI findings were suggestive of Moyamoya disease. This report underscores the rarity of the co-occurrence of B-ALL and Moyamoya disease and highlights the importance of early recognition and timely intervention during chemotherapy to reduce the risk of neurological complications. Our findings may offer valuable insights for the chemotherapeutic management of ALL patients with coexisting Moyamoya disease.<\/jats:p>","DOI":"10.3389\/fonc.2026.1733347","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:23:04Z","timestamp":1771478584000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Chemotherapy management of a pediatric B-ALL patient with moyamoya disease: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Yi-ren","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi-yi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.5853\/jos.2015.01627","article-title":"Moyamoya disease: epidemiology, clinical features, and diagnosis","volume":"18","author":"Kim","year":"2016","journal-title":"J Stroke"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00165-X","article-title":"Moyamoya disease: diagnosis and interventions","volume":"21","author":"Ihara","year":"2022","journal-title":"Lancet Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1159\/000072872","article-title":"Moyamoya syndrome after prophylactic cranial irradiation for acute lymphocytic leukemia","volume":"39","author":"Kondoh","year":"2003","journal-title":"Pediatr Neurosurg"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2013.03.004","article-title":"Risk of first and recurrent stroke in childhood cancer survivors treated with cranial and cervical radiation therapy","volume":"86","author":"Mueller","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20837","article-title":"Moyamoya syndrome following childhood acute lymphoblastic leukemia","volume":"48","author":"Kikuchi","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"5515","DOI":"10.3390\/ijms23105515","article-title":"Neurotoxicity associated with treatment of acute lymphoblastic leukemia chemotherapy and immunotherapy","volume":"23","author":"\u015aliwa-Tytko","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s13760-024-02602-0","article-title":"Central nervous system complications during treatment in childhood acute leukemia","volume":"125","author":"Ekici","year":"2025","journal-title":"Acta Neurol Belg"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.280016","article-title":"Acute central nervous system toxicity during treatment of pediatric acute lymphoblastic leukemia: phenotypes, risk factors and genotypes","volume":"107","author":"Anastasopoulou","year":"2022","journal-title":"Haematologica"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21665","article-title":"Prospective study of hemostatic alterations in children with acute lymphoblastic leukemia","volume":"85","author":"Giordano","year":"2010","journal-title":"Am J Hematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06677.x","article-title":"Thrombosis and acute lymphoblastic leukaemia","volume":"138","author":"Payne","year":"2007","journal-title":"Br J Haematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2018.24","article-title":"Pharmacogenetics of asparaginase in acute lymphoblastic leukemia","volume":"2","author":"Abaji","year":"2019","journal-title":"Cancer Drug Resist"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12947","article-title":"A randomized phase I study to evaluate the safety, tolerability, and pharmacokinetics of recombinant erwinia asparaginase (JZP-458) in healthy adult volunteers","volume":"14","author":"Lin","year":"2021","journal-title":"Clin Transl Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.282324","article-title":"Back to the future: the amazing journey of the therapeutic anti-leukemia enzyme asparaginase Erwinia chrysanthemi","volume":"108","author":"Tong","year":"2023","journal-title":"Haematologica"},{"key":"B14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/nyas.12496","article-title":"Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia","volume":"1329","author":"Salzer","year":"2014","journal-title":"Ann N Y Acad Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.5114\/aoms\/125544","article-title":"Comparison of the efficacy of vindesine and leurocristine for pediatric acute lymphoblastic leukemia and their effects on quality of life","volume":"17","author":"Shi","year":"2021","journal-title":"Arch Med Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1177\/0883073819844854","article-title":"Surgery for moyamoya disease in children","volume":"34","author":"Appireddy","year":"2019","journal-title":"J Child Neurol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1159\/000448314","article-title":"Moyamoya disease","volume":"40","author":"Fujimura","year":"2016","journal-title":"Front Neurol Neurosci"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1733347\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:23:05Z","timestamp":1771478585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1733347\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":17,"alternative-id":["10.3389\/fonc.2026.1733347"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1733347","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"article-number":"1733347"}}